LEN lenacapavir

DHHS recommendation not established
Long-acting Capsid Inhibitor

Standard Dose

Lenacapavir is a long-acting subcutaneous injection administered once every six months by a healthcare provider.

In the Phase 2/3 CAPELLA clinical trial for heavily treatment-experienced individuals, two 300 mg tablets were given on Day 1 and Day 2 and one 300 mg tablet was given on Day 8 as an oral initiation. On Day 15, a maintenance dose of 927 mg (two 1.5 mL injections) was administered by subcutaneous injection into the abdomen, and was then injected every six months thereafter.
Lenacapavir must be taken in combination with other antiretroviral(s).

• See package insert when available for more complete information on potential side effects and interactions. 


Gilead Sciences, Inc.
(800) GILEAD-5 (445-3235)


Lenacapavir was not yet on the market as this issue went to press

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments